Ultrasound molecular imaging of arterial thrombi with novel microbubbles modified by cyclic RGD in vitro and in vivo

Summary

Despite immense potential, ultrasound molecular imaging (UMI) of arterial thrombi remains very challenging because the high-shear arterial flow limits binding of site-targeted microbubbles to the thrombi. The linear Arg-Gly-Asp (RGD) peptides have been successfully applied to evaluate venous, atrial, and arteriolar thrombi, but have thus far failed in the detection of arterial thrombi. Cyclic RGD (Arg-Gly-Asp-D-Phe-Cys) is a cyclic conformation of linear RGD peptides, which has much higher binding-affinity and selectivity for binding to the glycoprotein (GP) IIb/IIIa receptor than its linear counterpart and thus is likely to be an optimal targeted molecular probe for ultrasound molecular imaging of arterial thrombi. In this study, we sought to assess the feasibility of a novel microbubble conjugated with cyclic RGD (Mb-cyclic RGD) in UMI of arterial thrombi in vitro and in vivo. As expected, Mb-cyclic RGD had greater GP IIb/IIIa-targeted binding capability in all shear stress conditions. In addition, the shear stress at half-maximal detachment of Mb-cyclic RGD was 5.7-fold higher than that of microbubbles with nonspecific peptide (Mb-CON) (p<0.05). Mb-cyclic RGD enhanced the echogenicity of the platelet-rich thrombus in vitro whereas Mb-CON did not produce enhancement. In the in vivo setting, optimal signal enhancement of the abdominal aortic thrombus was displayed with Mb-cyclic RGD in all cases. Mean video intensity of the abdominal aortic thrombi with Mb-cyclic RGD was 3.2-fold higher than that with Mb-CON (p<0.05). The novel Mb-cyclic RGD facilitated excellent visualisation of arterial thrombi using UMI and showed great promise for clinical applications.

Keywords

Ultrasound molecular imaging - arterial thrombus - cyclic RGD - microbubbles

^* These authors contributed equally to this work.

• References

• 1 Ebbesen LS. Hyperhomocysteinemia, thrombosis and vascular biology. Cellular and molecular biology (Noisy-le-Grand, France) 2004; 50: 917-930.
• 2 Naemura A, Ohira H, Ikeda M. et al. An experimentally antithrombotic strawberry variety is also effective in humans. Pathophysiol Haemost Thromb 2006; 35: 398-404.
• 3 Shantaram V. Pathogenesis of atherosclerosis in diabetes and hypertension. Clin Exp Hypertens 1999; 21: 69-77.
• 4 Corti R, Osende JI, Fayad ZA. et al. In vivo noninvasive detection and age definition of arterial thrombus by MRI. J Am Coll Cardiol 2002; 39: 1366-1373.
• 5 Saraste A, Nekolla SG, Schwaiger M. Cardiovascular molecular imaging: an overview. Cardiovasc Res 2009; 83: 643-652.
• 6 Hwang M, Lyshchik A, Fleischer AC. Molecular sonography with targeted micro-bubbles: current investigations and potential applications. Ultrasound Quart 2010; 26: 75-82.
• 7 Alonso A, Della Martina A, Stroick M. et al. Molecular imaging of human thrombus with novel abciximab immunobubbles and ultrasound. Stroke 2007; 38: 1508-1514.
• 8 Lowe GD. Virchow's triad revisited: abnormal flow. Pathophysiol Haemost Thromb 2003; 33: 455-457.
• 9 Stoll P, Bassler N, Hagemeyer CE. et al. Targeting ligand-induced binding sites on GPIIb/IIIa via single-chain antibody allows effective anticoagulation without bleeding time prolongation. Arterioscl Thromb Vasc Biol 2007; 27: 1206-1212.
• 10 Plow EF, Cierniewski CS, Xiao Z. et al. AlphaIIbbeta3 and its antagonism at the new millennium. Thromb Haemost 2001; 86: 34-40.
• 11 Haas TA. Allosteric regulation of alpha(IIb)beta(3) by beta(3) 95-105. Thromb Haemost 2008; 99: 701-710.
• 12 Unger EC, McCreery TP, Sweitzer RH. et al. In vitro studies of a new thrombus-specific ultrasound contrast agent. Am J Cardiol 1998; 81: 58G-61G.
• 13 Takeuchi M, Ogunyankin K, Pandian NG. et al. Enhanced visualization of intravascular and left atrial appendage thrombus with the use of a thrombus-targeting ultrasonographic contrast agent (MRX-408A1): In vivo experimental echocardiographic studies. J Am Soc Echocardiogr 1999; 12: 1015-1021.
• 14 Schumann PA, Christiansen JP, Quigley RM. et al. Targeted-microbubble binding selectively to GPIIb IIIa receptors of platelet thrombi. Invest Radiol 2002; 37: 587-593.
• 15 Imura Y, Stassen JM, Vreys I. et al. Synergistic antithrombotic properties of G4120, a RGD-containing synthetic peptide, and argatroban, a synthetic thrombin inhibitor, in a hamster femoral vein platelet-rich thrombosis model. Thromb Haemost 1992; 68: 336-340.
• 16 Bogdanowich-Knipp SJ, Chakrabarti S, Williams TD. et al. Solution stability of linear vs. cyclic RGD peptides. J Pept Res 1999; 53: 530-541.
• 17 Bogdanowich-Knipp SJ, Jois DS, Siahaan TJ. The effect of conformation on the solution stability of linear vs. cyclic RGD peptides. J Pept Res 1999; 53: 523-529.
• 18 Wang Y, Goh SY, Kuczera K. Molecular dynamics study of disulfide bond influence on properties of an RGD peptide. J Pept Res 1999; 53: 188-200.
• 19 Kato M, Mrksich M. Using model substrates to study the dependence of focal adhesion formation on the affinity of integrin-ligand complexes. Biochemistry 2004; 43: 2699-2707.
• 20 Dijkgraaf I, Boerman OC, Oyen WJ. et al. Development and application of peptide-based radiopharmaceuticals. Anti-cancer Agents Med Chem 2007; 07: 543-551.
• 21 Liu S. Radiolabeled multimeric cyclic RGD peptides as integrin alphavbeta3 targeted radiotracers for tumor imaging. Mol Pharmaceutics 2006; 03: 472-487.
• 22 Liu S. Radiolabeled cyclic RGD peptides as integrin alpha(v)beta(3)-targeted radiotracers: maximizing binding affinity via bivalency. Bioconj Chem 2009; 20: 2199-2213.
• 23 Sinha D, Shukla G, Chuttani K. et al. Synthesis and biological evaluation of (99m)Tc-DTPA-bis(His) as a potential probe for tumor imaging with SPECT. Cancer Biother Radiopharm 2009; 24: 615-620.
• 24 Basly B, Felder-Flesch D, Perriat P. et al. Dendronized iron oxide nanoparticles as contrast agents for MRI. Chemical Comm 2010; 46: 985-987.
• 25 Klibanov AL. Ligand-carrying gas-filled microbubbles: ultrasound contrast agents for targeted molecular imaging. Bioconj Chem 2005; 16: 9-17.
• 26 Anderson CR, Rychak JJ, Backer M. et al. scVEGF microbubble ultrasound contrast agents: a novel probe for ultrasound molecular imaging of tumor angiogenesis. Invest Radiol 2010; 45: 579-585.
• 27 Xie H, Diagaradjane P, Deorukhkar AA. et al. Integrin alphavbeta3-targeted gold nanoshells augment tumor vasculature-specific imaging and therapy. Int J Nanomed 2011; 06: 259-269.
• 28 Takalkar AM, Klibanov AL, Rychak JJ. et al. Binding and detachment dynamics of microbubbles targeted to P-selectin under controlled shear flow. J Control Release 2004; 96: 473-482.
• 29 Klibanov AL, Rychak JJ, Yang WC. et al. Targeted ultrasound contrast agent for molecular imaging of inflammation in high-shear flow. Contrast Media Mol Imag 2006; 01: 259-266.
• 30 Higuchi T, Bengel FM, Seidl S. et al. Assessment of alphavbeta3 integrin expression after myocardial infarction by positron emission tomography. Cardiovasc Res 2008; 78: 395-403.
• 31 Martin MJ, Chung EM, Goodall AH. et al. Enhanced detection of thromboemboli with the use of targeted microbubbles. Stroke 2007; 38: 2726-2732.
• 32 Haubner R, Bruchertseifer F, Bock M. et al. Synthesis and biological evaluation of a (99m)Tc-labelled cyclic RGD peptide for imaging the alphavbeta3 expression. Nuklearmed 2004; 43: 26-32.
• 33 Dunehoo AL, Anderson M, Majumdar S. et al. Cell adhesion molecules for targeted drug delivery. J Pharmaceut Sci 2006; 95: 1856-1872.
• 34 Haubner R, Wester HJ. Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. Curr Pharmaceut Design 2004; 10: 1439-1455.
• 35 Haubner R. Alphavbeta3-integrin imaging: a new approach to characterise angiogenesis?. Eur J Nuclear Med Mol Imag 2006; 33 (01) 54-63.
• 36 Seo JW, Mahakian LM, Kheirolomoom A. et al. Liposomal Cu-64 Labeling Method Using Bifunctional Chelators: Poly(ethylene glycol) Spacer and Chelator Effects. Bioconjug Chem 2010; 21: 1206-1215.
• 37 Feldwisch J, Tolmachev V, Lendel C. et al. Design of an optimized scaffold for affibody molecules. J Mol Biol 2010; 398: 232-247.
• 38 Cherkaoui S, Bettinger T, Hauwel M. et al. Tracking of antibody reduction fragments by capillary gel electrophoresis during the coupling to microparticles surface. J Pharma Biomed Anal 2010; 53: 172-178.
• 39 Choi H, Aboulfatova K, Pownall HJ. et al. Shear-induced disulfide bond formation regulates adhesion activity of von Willebrand factor. J Biol Chem 2007; 282: 35604-35611.
• 40 Li Y, Choi H, Zhou Z. et al. Covalent regulation of ULVWF string formation and elongation on endothelial cells under flow conditions. J Thromb Haemost 2008; 06: 1135-1143.
• 41 Kaufmann BA, Lindner JR. Molecular imaging with targeted contrast ultrasound. Curr Opin Biotechnol 2007; 18: 11-16.
• 42 Lanza GM, Wallace KD, Scott MJ. et al. A novel site-targeted ultrasonic contrast agent with broad biomedical application. Circulation 1996; 94: 3334-3340.
• 43 Gupta AS, Huang G, Lestini BJ. et al. RGD-modified liposomes targeted to activated platelets as a potential vascular drug delivery system. Thromb Haemost 2005; 93: 106-114.
• 44 Chen H, Mo W, Su H. et al. Characterization of a novel bifunctional mutant of staphylokinase with platelet-targeted thrombolysis and antiplatelet aggregation activities. BMC molecular Biol 2007; 08: 88.
• 45 Kochanowski R, Kotlowski R, Szweda P. Expression and intein-mediated purification of novel staphylokinase SakSTAR with reduced immunogenicity and antiplatelet and antithrombin activation. Appl Biochem Biotechnol 2007; 141: 321-333.